首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5203篇
  免费   194篇
  国内免费   172篇
耳鼻咽喉   5篇
儿科学   17篇
妇产科学   18篇
基础医学   181篇
口腔科学   5篇
临床医学   1257篇
内科学   713篇
皮肤病学   18篇
神经病学   46篇
特种医学   112篇
外科学   1379篇
综合类   935篇
预防医学   373篇
眼科学   1篇
药学   403篇
  14篇
中国医学   76篇
肿瘤学   16篇
  2024年   4篇
  2023年   47篇
  2022年   117篇
  2021年   138篇
  2020年   171篇
  2019年   108篇
  2018年   90篇
  2017年   132篇
  2016年   126篇
  2015年   180篇
  2014年   429篇
  2013年   431篇
  2012年   448篇
  2011年   443篇
  2010年   296篇
  2009年   280篇
  2008年   265篇
  2007年   250篇
  2006年   210篇
  2005年   228篇
  2004年   179篇
  2003年   150篇
  2002年   126篇
  2001年   108篇
  2000年   73篇
  1999年   64篇
  1998年   62篇
  1997年   48篇
  1996年   29篇
  1995年   54篇
  1994年   41篇
  1993年   24篇
  1992年   15篇
  1991年   16篇
  1990年   22篇
  1989年   17篇
  1988年   13篇
  1987年   20篇
  1986年   15篇
  1985年   23篇
  1984年   30篇
  1983年   22篇
  1982年   3篇
  1981年   4篇
  1980年   4篇
  1978年   2篇
  1977年   3篇
  1976年   3篇
  1975年   3篇
  1973年   1篇
排序方式: 共有5569条查询结果,搜索用时 131 毫秒
1.
目的分析维持性血液透析患者发生结核感染的影响因素及临床特点。方法回顾性调查2018年5月-2019年8月北京清华长庚医院肾内科收治的长期规律血液透析患者共150例,收集患者的年龄、性别、合并疾病、血常规、生化、透析充分性等检验结果和影像学资料,归纳分析血液透析患者发生结核感染的影响因素。结果150例血液透析患者,男性91人,女性59人,平均年龄(62.7±14.2)岁,发生结核感染者共11例(7.33%),其中肺外结核比例高(54.5%),以浆膜腔积液为主要表现(54.5%),血红蛋白(94.7±11.6)g/L、血清白蛋白(34.6±2.0)g/L、血肌酐(593.6±221.4)umol/L低于无结核感染者,差异具有统计学意义(P<0.05);血小板(228.7±103.5)×109/L高于无结核感染者,差异具有统计学意义(P<0.05)。两组患者年龄、透析充分性、淋巴细胞、血糖、血脂、血钙、血磷、全段甲状旁腺激素无统计学差异。结论血红蛋白<110g/L、白蛋白<35g/L是MHD患者发生结核感染的高危因素,MHD患者发生结核感染以肺外结核为主,临床表现具有隐匿性和不典型性,临床工作应提高警惕避免漏诊。  相似文献   
2.
IntroductionChronic inflammation and the underlying cardiovascular comorbidity are still current problems in chronic hemodialysis patients. There are few studies comparing the “dialysis dose” (Kt/V) with the degree of inflammation in the patient. Our main objective was to determine whether there is a relationship between serum C-reactive protein (CRP) levels and the Kt/V using ionic dialysance.MethodsMulticenter cross-sectional study. A total of 536 prevalent chronic hemodialysis patients were included. CRP levels, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were collected. Kt was obtained by ionic dialysance and urea distribution volume was calculated from the Watson's formula. The sample was divided into 2 groups, taking the median CRP as the cut-off point. Dialysis adequacy obtained in each group was compared. Finally, a logistic regression model was carried out to determine the variables with the greatest influence.ResultsMedian CRP was 4.10 mg/L (q25-q75: 1.67-10) and mean Kt/V was 1.48 ± 0.308. Kt/V was lower in the patients included in the high inflammation group (P = .01). In the multivariate logistic regression, the “high” levels of CRP were directly correlated with the Log neutrophil-lymphocyte ratio (P < .001) and inversely proportional with serum albumin values (P = .014), Kt/V (P = .037) and serum iron (P < .001).ConclusionThe poorer adequacy in terms of dialysis doses (lower Kt/V values) may contribute to a higher degree of inflammation in chronic hemodialysis patients.  相似文献   
3.
A new extracorporeal circuit for hemodialysis was designed with the goal of improving the middle and high molecular weight toxins removal. A recirculation pathway was added to the hemodialysis circuit and relevant pressure regulation was performed along the circuit in order to keep the ultrafiltration rate as zero. The influence of increasing the recirculation to dialysate flow rate ratio on the removal of urea, vitamin B12, and hemoglobin was investigated. This removal was also modeled by an analytical method and solved by MATLAB software. A significant increase in removal of vitamin B12 (34%) and especially hemoglobin (228%) was achieved using the recirculation flow in an adjusted hemodialysis circuit. The model showed an acceptable agreement with the experimental results which shows its applicability for prediction of different toxin removal in this circuit.  相似文献   
4.
目的 通过Meta分析了解留置中心静脉导管的血液透析患者发生导管相关血流感染的危险因素。 方法 计算机检索中国期刊全文数据库、万方数据库、维普数据库、中国生物医学文献数据库、Cochrane Library、PubMed、Web of Science、Embase数据库,检索时限为建库至2020年12月31日,使用RevMan 5.3进行Meta分析。结果 共纳入20篇文献,包括29项相关危险因素,有统计学意义的危险因素包括合并糖尿病(OR=2.55)、血清白蛋白<30 g/L(OR=2.35)、CD4+细胞<200个/μl(OR=3.02)、急性生理与慢性健康评分Ⅱ≥20分(OR=2.41)、股静脉置管(OR=1.94)、导管留置时间≥14 d(OR=3.20)、使用带隧道带涤纶套导管(OR=2.83)。 结论 合并糖尿病、低血清白蛋白、CD4+细胞<200个/μl、急性生理与慢性健康评分Ⅱ≥20分、股静脉置管、导管留置时间≥14 d、使用带隧道带涤纶套导管是留置中心静脉导管的血液透析患者易发生导管相关血流感染,护理人员应充分关注该类患者。  相似文献   
5.
6.
7.
目的 探讨血液透析病人并发脑出血预后的影响因素。方法 回顾性分析2013年7月至2018年7月收治的48例血液透析并发脑出血的临床资料。根据发病30 d改良Rankin量表(mRS)评分评估预后,0~2分为预后良好,3~6分为预后不良。采用多因素Logistic回归分析检验预后影响因素。结果 48例中,预后良好22例,预后不良26例。多因素Logistic回归分析显示年龄≥60岁、脑出血≥30 mL、入院时GCS评分≤12分、平均动脉压≥130 mmHg、白蛋白水平<30 g/dl是预后不良的独立危险因素(P<0.05)。结论 血液透析病人并发脑出血的预后较差,需要全面评估脑出血风险,采用及早、有针对性的干预,积极控制脑出血量,稳定血压和白蛋白水平,以期减少并发症和改善预后。  相似文献   
8.

Objective

Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in promoting radiocephalic fistula patency and use for hemodialysis.

Methods

PATENCY-1 was a double-blind, placebo-controlled trial that enrolled 349 patients on or approaching hemodialysis and being evaluated for radiocephalic arteriovenous fistula creation. Of these, 313 were randomized and 311 treated. Patients were assigned to vonapanitase (n = 210) or placebo (n = 103). The study drug solution was applied topically to the artery and vein for 10 minutes immediately after fistula creation. The primary and secondary end points were primary patency (time to first thrombosis or corrective procedure) and secondary patency (time to abandonment). Tertiary end points included use of the fistula for hemodialysis, fistula maturation by ultrasound, and procedure rates.

Results

The Kaplan-Meier estimates of 12-month primary patency were 42% (95% confidence interval [CI], 35-49) and 31% (95% CI, 21-42) for vonapanitase and placebo (P = .25). The Kaplan-Meier estimates of 12-month secondary patency were 74% (95% CI, 68-80) and 61% (95% CI, 51-71) for vonapanitase and placebo (P = .048). The proportions of vonapanitase and placebo patients were 39% and 25% (P = .035) with unassisted use for hemodialysis and 64% and 44% (P = .006) with unassisted plus assisted use.

Conclusions

Vonapanitase treatment did not significantly improve primary patency but was associated with increased secondary patency and use for hemodialysis. Further research is needed to evaluate these end points.  相似文献   
9.
10.
BackgroundOur aim was to elucidate whether Hb variability affects nutritional status in HD patients.MethodsThis study included chronic HD patients (n = 76) with available monthly Hb levels up to 24 months prior to the body composition monitoring (BCM) measurement. The parameters obtained in the BCM included body mass index (BMI), lean tissue index (LTI), fat tissue index (FTI), body cell mass index (BCMI), overhydration/extracellular water ratio (OH), and phase angle (PhA). The coefficient of variation (Hb-CV), standard deviation (Hb-SD), and range of Hb (Hb-RAN) were used as indexes of Hb variability. In addition, minimum (Hb-Min), maximum (Hb-Max), average (Hb-Avg), and median (Hb-Med) Hb levels (g/dL) were analyzed.ResultsThere were no significant differences in clinical, biochemical, and nutritional indexes based on the Hb-CV level. Compared to patients with an Hb-Med ≤ 10.77, those with an Hb-Med >10.77 had higher albumin levels, total iron-binding capacity (TIBC), and PhA and lower average weekly prescribed darbepoetin. Age, female sex, OH, and darbepoetin dosage were negatively correlated with PhA. Serum albumin, phosphorus, TIBC, Hb-Med, and Hb-Avg were positively correlated with PhA. In multiple linear regression analysis, PhA was positively associated with Hb-Med and serum albumin level, whereas PhA was negatively associated with age and female sex. The area under the curve (AUC) of Hb-Med was 0.665 (p = 0.040) in predicting PhA >5.00°ConclusionsPhA was not affected by indexes of Hb variability, whereas PhA was associated with Hb-Med in chronic HD patients.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号